The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N05 | Psycholeptics | |
3
|
N05A | Antipsychotics | |
4
|
N05AX | Other antipsychotics | |
5
|
N05AX16 |
| Active Ingredient |
|---|
|
Brexpiprazole is an atypical antipsychotic agent. The pharmacology of brexpiprazole is believed to be mediated by a modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors, with similar high affinities at all of these receptors. |
| Document | Type | Information Source | |
|---|---|---|---|
| REXULTI Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| RXULTI Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.